Loading...
Targeting Solid Tumors With BTK Inhibitors
The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use...
Na minha lista:
| Udgivet i: | Front Cell Dev Biol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8079762/ https://ncbi.nlm.nih.gov/pubmed/33937249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2021.650414 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|